<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643811</url>
  </required_header>
  <id_info>
    <org_study_id>1210552-1</org_study_id>
    <nct_id>NCT01643811</nct_id>
  </id_info>
  <brief_title>Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients</brief_title>
  <official_title>Effect of Gastrectomy and Anastomosis on Chronic Metabolic Disease Such as Diabetes and Hypertension in Early Gastric Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the extent of gastrectomy and anastomosis
      type affect chronic metabolic disease such as diabetes and hypertension in early gastric
      cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who quit previous medication for diabetes because of improved disease</measure>
    <time_frame>5 year after operation</time_frame>
    <description>proportion of patients who quit their previous medication for diabetes because of improved disease after operation among all patients who underwent gastrectomy for early gastric cancer with diabetes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who quit previous medication for hypertension because of improved disease</measure>
    <time_frame>5 years after operation</time_frame>
    <description>Proportion of patients who quit previous medication for hypertension because of improved disease among the patients who diagnosed as early gastric cancer and hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference of proportion of patients who quit previous medication for diabetes between patients who underwent subtotal gastrectomy and those who underwent total gastrectomy</measure>
    <time_frame>5 years after operation</time_frame>
    <description>difference of proportion of patients who quit previous medication for diabetes between patients who underwent subtotal gastrectomy and those who underwent total gastrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of proportion of patients who quit previous medication for diabetes according to anastomosis</measure>
    <time_frame>5 year after operation</time_frame>
    <description>difference of proportion of patients who quit previous medication for diabetes among patients who underwent gastroduodenostomy and loop gastrojejunostomy and Roux-Y gastrojejunostomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of proportion of patients who quit previous medication for hypertension between patients who underwent subtotal gastrectomy and those who underwent total gastrectomy</measure>
    <time_frame>5 years after operation</time_frame>
    <description>difference of proportion of patients who quit previous medication for hypertension between patients who underwent subtotal gastrectomy and those who underwent total gastrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of proportion of patients who quit previous medication for hypertension according to anastomosis</measure>
    <time_frame>5 years after operation</time_frame>
    <description>difference of proportion of patients who quit previous medication for hypertension among patients who underwent gastroduodenostomy and loop gastrojejunostomy and Roux-Y gastrojejunostomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation</measure>
    <time_frame>1 years after operation</time_frame>
    <description>difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation in patients with diabetes</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">159</enrollment>
  <condition>Early Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Gastrectomy</arm_group_label>
    <description>Patients who underwent gastrectomy for early gastric cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopic submucosal dissection</arm_group_label>
    <description>Patients who underwent endoscopic submucosal dissection for early gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gastrectomy</intervention_name>
    <description>subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy</description>
    <arm_group_label>Gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic submucosal dissection</intervention_name>
    <description>endoscopic submucosal dissection</description>
    <arm_group_label>Endoscopic submucosal dissection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients diagnosed as early gastric cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven primary gastric adenocarcinoma

          -  clinical stage Ia or Ib examined with endoscopy, endoscopic ultrasound, and computed
             tomography

          -  aged 20-80 year old,

          -  performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale

          -  diagnosed as diabetes or hypertension

          -  patients planning to undergo gastrectomy or endoscopic submucosal dissection

          -  written informed consent

        Exclusion Criteria:

          -  having high risk for operation such as severe heart disease, severe respiratory
             disease

          -  pregnant

          -  previous abdominal surgery or radiation therapy

          -  proven more advanced disease than pathological stage II requiring adjuvant
             chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <state>Kyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Keun Won Ryu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>early gastric cancer, diabetes, hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

